Pneumonectomy After Induction Therapy for Stage IIIA Non-small-cell Lung Cancer

摘要: Multimodality treatment has become the standard of care for locally advanced non small lung cancer (NSCLC). However, several observational studies in past have shown that induction may increase risk perioperative complications and mortality after pneumonectomy, questioning real benefit surgery when a resection greater than lobectomy is anticipated. Based on these findings, most current guidelines1,2 emphasize pneumonectomy do not recommend this operation chemotherapy or chemoradiotherapy, indicate stage IIIA NSCLC patients should be chemoradiotherapy outside clinical trials. Therefore, multimodality including carefully weighed against increased early mortality, severe complications, impaired quality life long term disability. practice, surgeons are often driven more by personal experience attitudes scientific evidence, particularly evidence weak topic still controversial.